This study confirms that the combination treatment can downregulate Nrf2 by inhibiting the Nrf2 axis, which is beneficial for inhibiting the growth of HCC as well as inducing autophagy and apoptosis in tumor cells. The gene discussed is NFE2L2; the disease is hepatocellular carcinoma.